Department of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.
Department of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland; Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pharmacol Res. 2020 Jun;156:104793. doi: 10.1016/j.phrs.2020.104793. Epub 2020 Apr 8.
Sphingosine-1-phosphate (S1P) is a signaling lipid, synthetized by sphingosine kinases (SPHK1 and SPHK2), that affects cardiovascular function in various ways. S1P signaling is complex, particularly since its molecular action is reliant on the differential expression of its receptors (S1PR1, S1PR2, S1PR3, S1PR4, S1PR5) within various tissues. Significance of this sphingolipid is manifested early in vertebrate development as certain defects in S1P signaling result in embryonic lethality due to defective vasculo- or cardiogenesis. Similar in the mature organism, S1P orchestrates both physiological and pathological processes occurring in the heart and vasculature of higher eukaryotes. S1P regulates cell fate, vascular tone, endothelial function and integrity as well as lymphocyte trafficking, thus disbalance in its production and signaling has been linked with development of such pathologies as arterial hypertension, atherosclerosis, endothelial dysfunction and aberrant angiogenesis. Number of signaling mechanisms are critical - from endothelial nitric oxide synthase through STAT3, MAPK and Akt pathways to HDL particles involved in redox and inflammatory balance. Moreover, S1P controls both acute cardiac responses (cardiac inotropy and chronotropy), as well as chronic processes (such as apoptosis and hypertrophy), hence numerous studies demonstrate significance of S1P in the pathogenesis of hypertrophic/fibrotic heart disease, myocardial infarction and heart failure. This review presents current knowledge concerning the role of S1P in the cardiovascular system, as well as potential therapeutic approaches to target S1P signaling in cardiovascular diseases.
鞘氨醇-1-磷酸(S1P)是一种信号脂质,由鞘氨醇激酶(SPHK1 和 SPHK2)合成,以多种方式影响心血管功能。S1P 信号通路非常复杂,特别是由于其分子作用依赖于其受体(S1PR1、S1PR2、S1PR3、S1PR4、S1PR5)在不同组织中的差异表达。这种鞘脂的重要性在脊椎动物早期发育中就表现出来,因为 S1P 信号的某些缺陷会导致胚胎致死,原因是血管发生或心脏发生缺陷。在成熟的生物体中也是如此,S1P 协调真核生物心脏和血管中发生的生理和病理过程。S1P 调节细胞命运、血管张力、内皮功能和完整性以及淋巴细胞迁移,因此其产生和信号转导的失衡与动脉高血压、动脉粥样硬化、内皮功能障碍和异常血管生成等病理过程的发展有关。许多信号机制至关重要 - 从内皮型一氧化氮合酶通过 STAT3、MAPK 和 Akt 途径到参与氧化还原和炎症平衡的 HDL 颗粒。此外,S1P 控制急性心脏反应(心脏变力和变时性)以及慢性过程(如细胞凋亡和肥大),因此许多研究表明 S1P 在肥厚/纤维化性心脏病、心肌梗死和心力衰竭的发病机制中的重要性。本综述介绍了 S1P 在心血管系统中的作用以及针对心血管疾病中 S1P 信号的潜在治疗方法的最新知识。